SYT-SSX融合基因亚型与滑膜肉瘤细胞增殖及凋亡的关系  

The Relationship of SYT-SSX Fusion Genes with the Proliferation and Apoptosis of Tumor Cells in Synovial Sarcoma

作　　者：孙燕[1] 孙保存[1] 赵秀兰[2] 王健[3] 郝希山[3] 

机构地区：[1]天津市肿瘤防治重点实验室天津医科大学附属肿瘤医院病理科,天津市300060 [2]天津医科大学病理学教研室 [3]天津医科大学附属肿瘤医院胰腺肿瘤科

出　　处：《中国肿瘤临床》2009年第13期748-751,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金资助(编号:30572097)

摘　　要：目的:SYT-SSX融合基因是滑膜肉瘤的分子遗传学特征,影响滑膜肉瘤的发生发展,但作用机制不详。本研究通过分析SYT-SSX融合基因亚型与肿瘤细胞增殖及凋亡的关系,探讨SYT-SSX对滑膜肉瘤增殖、凋亡的影响。方法:选取141例SYT-SSX融合基因阳性的滑膜肉瘤,进行核分裂计数,通过Ki-67免疫组织化学染色计算Ki-67标记指数(labeling index,LI),反映肿瘤细胞的增殖情况;通过TUNEL染色计算凋亡指数(apoptosis index,AI),并结合Bcl-2和Bax免疫组织化学染色,分析肿瘤细胞的凋亡情况;最后,分析SYT-SSX亚型与核分裂数、Ki-67 LI、AT及Bcl-2、Bax表达的关系。结果:SYT-SSX1和SYT-SSX2阳性滑膜肉瘤分别为50例和91例;SYT-SSX1型和SYT-SSX2型滑膜肉瘤的核分裂数分别为(15.58±9.18)/10HPF和(11.02±8.78)/10HPF,前者显著高于后者(t=2.902,P=0.004);并且,SYT-SSX1型和SYT-SSX2型滑膜肉瘤的Ki-67 LI分别为(25.26±12.78)%和(19.77±11.44)%,前者明显高于后者(t=2.615,p=0.010)。另外,SYT-SSX1与SYT-SSX2型滑膜肉瘤的AI分别为(1.66±1.84)%和(1.65±2.22)%,两组无统计学差异(t=0.022,P=0.982);不同SYT-SSX亚型病例的Bcl-2和Bax表达情况无明显差别(分别P=0.156,P=0.321)。结论:SYT-SSX融合基因亚型可能影响滑膜肉瘤肿瘤细胞的增殖,SYT-SSX1型病例肿瘤细胞的增殖能力较强;但是,SYT-SSX1与SYT-SSX2可能在调节细胞凋亡方面的能力无明显差别。Objective： SYT-SSX fusion genes are the characteristics of molecular genetics and affect the development and progress of synovial sarcomas. The mechanism of SYT-SSX, however, is not clear. In this study, we analyzed the relationship of SYT-SSX fusion type with the proliferation and apoptosis of tumor cells in order to explore the influence of SYT-SSX fusion genes on the proliferation and apoptosis of synovial sarcoma cells. Methods： Immunohistochemistry staining of Ki-67, Bcl-2 and Bax and TUNEL staining were performed in 141 samples of synovial sarcoma which were positive for SYT-SSX. Mitotic rate and Ki-67 labeling index （LI） were counted to evaluate the the proliferation of tumor cells. Then, the apoptosis index （AI） and expression of Bcl-2 and Bax were analyzed to evaluate the apoptosis of tumor cells. At last, the relationship of SYT-SSX fusion type with mitotic rate, Ki-67 LI, AI, and expression of Bcl-2 and Bax were analyzed. Results： SYT-SSX1 and SYT-SSX2 were positive in 50 and 91 synovial sarcomas, respectively. The mitotic rate was 15.58±9.18/10HPF in SYT-SSXl group and 11.02±8.78/10HPF in SYT-SSX2 group, with a significant difference （t=2.902, P=0.004）. Moreover, Ki-67 LI was 25.26%±12.78% in SYT-SSXl group and 19.77%±11.44% in SYT-SSX2 group, with a significant difference （t=2.615, P=-0.010）. Furthermore, AI was 1.66%±1.84% in SYT-SSX1 group and 1.65%±2.22% in SYT-SSX2 group, with no significant difference （t=-0.022, P=0.982）. In addition, there was no statistical difference in the expression of Bcl-2 （P=-0.156） and Bax （P=0.321） between SYT-SSX1 group and SYT-SSX2 group. Conclusion： SYT-SSX fusion genes possibly affect the proliferation of tumor cells of synovial sarcoma. The proliferative ability of tumor cells in SYT-SSXl positive sarcomas is stronger than that in SYT-SSX2 positive ones. Nevertheless, there is no significant difference in the ability controlling apoptosis between SYT-SSXl positive synovial sarcoma and SYT-SSX2 positive synovial sarcoma.

关 键 词：滑膜肉瘤 融合基因SYT—SSX 增殖 凋亡 

分 类 号：R738.5[医药卫生—肿瘤]